![Michael Cannon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Cannon
Direktor/Vorstandsmitglied bei
MOLECULIN BIOTECH, INC.
Vermögen: - $ am 31.08.2026
Profil
Michael D.
Cannon is currently Director at Osel, Inc. and Eureka Therapeutics, Inc. He is Independent Director at Moleculin Biotech, Inc. since 2015 and Executive Director at Biosentinel, Inc. since 2010.
Former roles include Director, Chief Science Officer & Executive VP at SICOR, Inc. from 1997 to 2004.
Other former positions include Director at Metabasis Therapeutics, Inc., Independent Director at Athenex, Inc., Director at Waterstone Pharmaceuticals, Inc., Director at Antiva Biosciences, Inc., and Strategic Partner at Trevi Management LP.
Education includes undergraduate studies at Fordham University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.08.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
Aktive Positionen von Michael Cannon
| Unternehmen | Position | Beginn |
|---|---|---|
| MOLECULIN BIOTECH, INC. | Direktor/Vorstandsmitglied | 01.07.2015 |
Eureka Therapeutics, Inc.
 Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Direktor/Vorstandsmitglied | - |
Osel, Inc.
 Osel, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes live biotherapeutic products that prevent abnormal conditions resulting from a disruption of the human microbiome | Direktor/Vorstandsmitglied | - |
Biosentinel, Inc.
 Biosentinel, Inc. BiotechnologyHealth Technology Develops tests for the detection of the botulinum neurotoxins | Direktor/Vorstandsmitglied | 01.07.2010 |
Ehemalige bekannte Positionen von Michael Cannon
| Unternehmen | Position | Ende |
|---|---|---|
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 |
| ATHENEXPAR | Direktor/Vorstandsmitglied | - |
Antiva Biosciences, Inc.
 Antiva Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics | Direktor/Vorstandsmitglied | - |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Direktor/Vorstandsmitglied | - |
Waterstone Pharmaceuticals, Inc.
 Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Direktor/Vorstandsmitglied | - |
Ausbildung von Michael Cannon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
35
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Health Technology |
Athenex, Inc.
 Athenex, Inc. BiotechnologyHealth Technology Develops and commercializes drugs for cancer and immunomodulatory diseases | Health Technology |
Osel, Inc.
Osel, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes live biotherapeutic products that prevent abnormal conditions resulting from a disruption of the human microbiome | Health Technology |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Health Technology |
Waterstone Pharmaceuticals, Inc.
Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Health Technology |
Antiva Biosciences, Inc.
Antiva Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics | Health Technology |
Fordham University
 Fordham University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Management LP
 Trevi Management LP Investment ManagersFinance Trevi Health Capital seeks investment opportunities in middle market companies across the globe. The firm focuses on healthcare sectors such as healthcare information technology, healthcare services, and medical technology. It participates in growth stages, traditional buyouts, special situations, and structured finance transactions with an investment size of at least USD 500 million. It also acts as a lead or co-lead investor. | Finance |
Moleculin Biotech, Inc.
 Moleculin Biotech, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of treatments for highly resistant cancers and viruses | Health Technology |
Biosentinel, Inc.
Biosentinel, Inc. BiotechnologyHealth Technology Develops tests for the detection of the botulinum neurotoxins | Health Technology |
